share_log

TIGERMED: 2024 ANNUAL REPORT

HKEX ·  Apr 29 16:43

Summary by Futu AI

泰格醫藥公佈2024年度業績,期內收入錄得66億元人民幣,同比下降10.6%;淨利潤為4.48億元人民幣,同比大幅下滑79.2%。公司現金持有量從74億元降至20.5億元人民幣,並宣佈派發每股0.30元人民幣的股息。公司年內研發支出為2.38億元人民幣,同比減少8.9%,主要用於員工成本、折舊及服務費用。在風險管理方面,公司持有64.5億元人民幣的可用銀行授信額度,並採取積極措施管理外匯風險,主要涉及美元和韓元的匯率波動。展望未來,泰格醫藥將持續專注於全球業務擴張,加大數字化轉型投入,並強化專業治療領域的專業知識。公司計劃通過戰略舉措和風險管理來適應具有挑戰性的市場環境,同時重視可持續發展。
泰格醫藥公佈2024年度業績,期內收入錄得66億元人民幣,同比下降10.6%;淨利潤為4.48億元人民幣,同比大幅下滑79.2%。公司現金持有量從74億元降至20.5億元人民幣,並宣佈派發每股0.30元人民幣的股息。公司年內研發支出為2.38億元人民幣,同比減少8.9%,主要用於員工成本、折舊及服務費用。在風險管理方面,公司持有64.5億元人民幣的可用銀行授信額度,並採取積極措施管理外匯風險,主要涉及美元和韓元的匯率波動。展望未來,泰格醫藥將持續專注於全球業務擴張,加大數字化轉型投入,並強化專業治療領域的專業知識。公司計劃通過戰略舉措和風險管理來適應具有挑戰性的市場環境,同時重視可持續發展。
TIGERMED announced its performance for the 2024 fiscal year, with revenue recorded at 6.6 billion yuan, a year-on-year decrease of 10.6%; net profit was 0.448 billion yuan, a substantial drop of 79.2%. The company's cash holdings decreased from 7.4 billion yuan to 2.05 billion yuan, and it announced a dividend of 0.30 yuan per share. During the year, the company's R&D expenditure was 0.238 billion yuan, down 8.9% year-on-year, mainly used for employee costs, depreciation, and service fees. In terms of risk management, the company holds a bank credit limit of 6.45 billion yuan and has taken proactive measures to manage Forex risk, primarily involving fluctuations in Exchange Rates for the US dollar and South Korean won. Looking ahead, TIGERMED will continue to focus on Global business expansion, increase investment in digital transformation, and strengthen expertise in the field of specialty care. The company plans to adapt to the challenging market environment through strategic initiatives and risk management while placing importance on sustainable development.
TIGERMED announced its performance for the 2024 fiscal year, with revenue recorded at 6.6 billion yuan, a year-on-year decrease of 10.6%; net profit was 0.448 billion yuan, a substantial drop of 79.2%. The company's cash holdings decreased from 7.4 billion yuan to 2.05 billion yuan, and it announced a dividend of 0.30 yuan per share. During the year, the company's R&D expenditure was 0.238 billion yuan, down 8.9% year-on-year, mainly used for employee costs, depreciation, and service fees. In terms of risk management, the company holds a bank credit limit of 6.45 billion yuan and has taken proactive measures to manage Forex risk, primarily involving fluctuations in Exchange Rates for the US dollar and South Korean won. Looking ahead, TIGERMED will continue to focus on Global business expansion, increase investment in digital transformation, and strengthen expertise in the field of specialty care. The company plans to adapt to the challenging market environment through strategic initiatives and risk management while placing importance on sustainable development.

The translation is provided by third-party software.


The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.